ArticleDiscover oncology2025
Reevaluating the role of surgery in lung cancer with liver metastases: a propensity score-matched survival analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lipid metabolism-related gene expression predicts prognostic outcomes in lung adenocarcinoma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundSurgery is the main modality of comprehensive tumor treatment, and there are fewer studies on surgery in lung cancer patients with liver metastases.
methodsIn this study, clinical data on lung cancer patients with liver metastases were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Patients treated with cancer-directed surgery (CDS) by Propensity Score Matching (PSM) are matched 1:1 to patients not treated with CDS. The impact of CDS treatment and clinical factors on patient prognosis was explored Kaplan-Meier survival analysis, univariate and multivariate Cox analysis, and Cox risk proportional regression models.
resultsA total of 6,632 lung cancer patients with liver metastases were included in this study, including 83 patients treated with CDS (1.25%) and 6549 patients not treated with CDS (98.75%). By PSM matching, 83 patients not treated with CDS were obtained. Survival analysis showed that the median survival was 9 months (95% CI 7-15 months) in the CDS group, compared to 3 months (95% CI 2-6 months) in the No-CDS group. Cox risk proportional regression models indicated that No-CDS, male and N2-N3 staging were prognostic risk factors, whereas chemotherapy were prognostic protective factors. In addition, univariate and multivariate Cox analyses showed that No-CDS and men were independent prognostic risk factors, whereas chemotherapy were independent prognostic protective factors.
conclusionsOur findings suggest that CDS treatment can improve the prognosis of patients with lung cancer with liver metastases, which will provide a reference for further randomized controlled clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.